The DOI matches its Crossref record; 220 of the 220 references it cites were found in a registry or an index.
Gene Therapy Leaves a Vicious Cycle
Open accessAbstract
The human genetic code encrypted in thousands of genes holds the secret for synthesis of proteins that drive all biological processes necessary for normal life and death. Though the genetic ciphering remains unchanged through generations, some genes get disrupted, deleted and or mutated, manifesting diseases, and or disorders. Current treatment options-chemotherapy, protein therapy, radiotherapy, and surgery available for no more than 500 diseases-neither cure nor prevent genetic errors but often cause many side effects. However, gene therapy, colloquially called "living drug," provides a one-time treatment option by rewriting or fixing errors in the natural genetic ciphering. Since gene therapy is predominantly a viral vector-based medicine, it has met with a fair bit of skepticism from both the science fraternity and patients. Now, thanks to advancements in gene editing and recombinant viral vector development, the interest of clinicians and pharmaceutical industries has been rekindled. With the advent of more than 12 different gene therapy drugs for curing cancer, blindness, immune, and neuronal disorders, this emerging experimental medicine has yet again come in the limelight. The present review article delves into the popular viral vectors used in gene therapy, advances, challenges, and perspectives.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–220 of 220
Genome Editing Techniques and Their Therapeutic Applications
Calos, M. P. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.542 · Cited by 26
Replication-competent herpes simplex vectors: design and applications
Argnani, R., Lufino, M. M., Manservigi, M., & Manservigi, R. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302622 · Cited by 24
Majima, T., Funahashi, Y., Takai, S., Goins, W. F., Gotoh, M., Tyagi, P., Glorioso, J. C., & Yoshimura, N. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.026 · Cited by 21
Germline editing dominates DNA summit
Travis, J. P. (2015) · Science · doi:10.1126/science.350.6266.1299 · Cited by 21
Dai, B., Roife, D., Kang, Y., Gumin, J., Perez, M. V. R., Li, X., Pratt, M. F., Brekken, R. A., Fueyo-Margareto, J., Lang, F. F., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0526 · Cited by 21
Kalimuthu, S., Oh, J. M., Gangadaran, P., Zhu, L., Lee, H., Jeon, Y. H., Jeong, S. Y., Lee, S., Lee, J., & Ahn, B. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181318 · Cited by 19
Ex Vivo and In Vivo Gene Delivery to the Brain
Suhonen, J., Ray, J., Blömer, U., et al. (2006) · Current Protocols in Human Genetics · doi:10.1002/0471142905.hg1303s51 · Cited by 18
Luo, H., Chen, Y., Ye, Z., Sun, X., Shi, Y., Luo, Q., Gong, B., Shuai, P., Yang, J., Zhou, Y., et al. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-16741 · Cited by 18
Novel role for p56/Lck in regulation of endothelial cell survival and angiogenesis
Betapudi, V., Shukla, M., Alluri, R. K., Merkulov, S. M., & McCrae, K. R. (2016) · The FASEB Journal · doi:10.1096/fj.201500040 · Cited by 18
Self-citationSuwanmanee, T., Ferris, M. T., Hu, P., Gui, T., Montgomery, S. A., de Villena, F. P., & Kafri, T. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.03.009 · Cited by 18
Wu, S., Li, M., Wang, S., Wang, W., Xi, L., Tian, X., Chen, G., Wu, Y., Zhou, J., Xu, G., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2567 · Cited by 17
Adenovirus transduction: More complicated than receptor expression
Sharma, P., Martis, P. C., & Excoffon, K. J. D. A. (2017) · Virology · doi:10.1016/j.virol.2016.12.020 · Cited by 16
Our journey to successful gene therapy for hemophilia B
Nathwani, A. C., Nienhuis, A. W., & Davidoff, A. M. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.2540 · Cited by 15 · cited 3×
“Use of immunosuppressive drugs was found safe to maintain therapeutic gene expression in many clinical trials (150, 220, 221), and their use could be an option for better clinical outcome, but maintenance of transgene expression remains unpredictable.”
BackgroundA novel Ad5/11 chimeric oncolytic adenovirus for improved glioma therapy
Li, X., Mao, Q., Wang, D., & Xia, H. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1674 · Cited by 11
Dutheil, N., Smith, S. C., Agúndez, L., Vincent‐Mistiaen, Z. I., Escalante, C. R., Linden, R. M., & Henckaerts, E. (2014) · Journal of Virology · doi:10.1128/jvi.00412-14 · Cited by 10
Gene therapy: Progress in childhood disease
Ginn, S. L., & Alexander, I. E. (2011) · Journal of Paediatrics and Child Health · doi:10.1111/j.1440-1754.2011.02204.x · Cited by 10
Pergament, E. (2016) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000255 · Cited by 6
Guo, L., Li, X., Yang, S., Xu, Y. Y., Tao, R., Wulan, H., Su, C., & Han, Y. (2014) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0000000000000364 · Cited by 5
Effects of Pharmacological Concentrations of Estrogens on Growth of 3AO Human Ovarian Cancer Cells
Zong-Bin, L. I., Yu-Xia, C. H. E. N., Zhao, J., & Lu, J. (2006) · Acta Genetica Sinica · doi:10.1016/s0379-4172(06)60111-x · Cited by 4
(1999) · PubMed
Cited by
CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future
Uddin, F., Rudin, C. M., & Sen, T. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01387 · Cited by 581
Non-viral Vectors in Gene Therapy: Recent Development, Challenges, and Prospects
Zu, H., & Gao, D. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00608-7 · Cited by 475
Localized Interleukin-12 for Cancer Immunotherapy
Nguyen, K. G., Vrabel, M. R., Mantooth, S. M., Hopkins, J. J., Wagner, E. S., Gabaldon, T. A., & Zaharoff, D. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.575597 · Cited by 431
Polymeric Delivery of Therapeutic Nucleic Acids
Kumar, R., Santa Chalarca, C. F., Bockman, M. R., Bruggen, C. V., Grimme, C. J., Dalal, R. J., Hanson, M. G., Hexum, J. K., & Reineke, T. M. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00997 · Cited by 365
AAV vectors: The Rubik’s cube of human gene therapy
Pupo, A., Fernández, A., Low, S. H., François, A., Suárez-Amarán, L., & Samulski, R. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.015 · Cited by 360
Metadata
- Authors
- Goswami, R., Subramanian, G., Silayeva, L., Newkirk, I., Doctor, D., Chawla, K., Chattopadhyay, S., Chandra, D., Chilukuri, N., & Betapudi, V.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2019-04-24
- Volume
- 9
- Pages
- 297-297
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2941417604
- Cited by
- 347
- References
- 220
- FWCI
- 28.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.